IMMURON Ltd/S (NASDAQ:IMRN) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price target of $20.00 for the company, according to Zacks. Zacks has also assigned IMMURON Ltd/S an industry rank of 112 out of 255 based on the ratings given to related companies.

Several research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of IMMURON Ltd/S in a research note on Wednesday, July 25th. ValuEngine raised shares of IMMURON Ltd/S from a “hold” rating to a “buy” rating in a research note on Wednesday, July 11th. Finally, Zacks Investment Research raised shares of IMMURON Ltd/S from a “sell” rating to a “hold” rating in a research note on Tuesday, June 12th.

IMMURON Ltd/S stock opened at $9.51 on Friday. IMMURON Ltd/S has a fifty-two week low of $4.63 and a fifty-two week high of $16.70.

About IMMURON Ltd/S

Immuron Limited, a biopharmaceutical company, focuses on the research and development of polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that produces antibodies to treat various diseases, including infectious diseases, cancers, and chronic inflammatory diseases.

See Also: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on IMMURON Ltd/S (IMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IMMURON Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMMURON Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.